RXIX - Daily Technical Program Schedule

Sunday 10 July 2022

Conference Check-In | Congress Foyer (-1)

14:00 - 16:00

16:00 -16:15 Conference Chair	Welcome by RXIX Conference Chairs Salone dei Cavalieri (-1) s Suzanne Farid, University College London (UCL), United Kingdom Nihal Tugcu, Sanofi, United States Arne Staby, Novo Nordisk, Denmark
Ovel Cossiers 1. De	Adenica Adenica Ducanica Dest Ducant & Fisture Cose Studies Salama dei Caroline (1)
Session Chairs:	espice, Adspice, Prospice – Past, Present & Future Case Studies Salone dei Cavalieri (-1) Jennifer Pollard, Merck and Co., Inc., United States Todd Przybycien, Rensselaer Polytechnic Institute, United States
16:15 - 16:20	Introduction by Session Chairs
16:20 - 16:45	What's old is new – Continuous countercurrent staging for chromatographic separations and precipitation Andrew Zydney, Penn State University, United States
16:45 - 17:10	Life-cycle Management and Process Enhancements for Over a Quarter-Century of Vaccine Supply Kristin Valente, Merck and Co., Inc., United States
17:10 - 17:35	Veni, Vidi, Exemplavi - The past, present and future of industrial chromatography modeling Felix Wittkopp, Roche Diagnostics GmbH, Germany
17:35 - 18:00	Purification Platform of the Future for Diverse Pipelines and Next Generation Manufacturing Benoit Mothes, Sanofi, France
18:00 - 19:30	Welcome Reception Tiepolo Terrace (0)
19:30 - 21:00	RXIX Opening Banquet Salone dei Cavalieri (-1)
After Dinner Keyı Host	note Salone dei Cavalieri (-1) Suzanne Farid, University College London (UCL), United Kingdom
21:00 - 21:45	The Anatomy of Hope Kevin Fong, University College London Hospitals (UCLH), United Kingdom
21:45 - 23:00	RXIX Rooftop Social Hour Terrazza degli Aranci (9)

Monday 11 July 2022

07:00 - 09:00 Breakfast | Le Bella Arti (-1)

Oral Session 2: A Call to Arms: Biotechnology's Approach to Address Pandemics | Salone dei Cavalieri (-1)

Session Chairs: Anne Kantardjieff, bluebird bio, United States
John Moscariello, Bristol Myers Squibb, United States

09:00 - 09:05 Introduction by Session Chairs

09:05 - 09:30 mRNA as a Platform for On-Demand Therapeutics and Pandemic Vaccines

Christopher Ladd Effio, Moderna, United States

09:30 - 09:55 Accelerated Development of Bamlanivimab

Richard Chen, Eli Lilly and Company, United States

09:55 - 10:20 Accelerated Development of Neutralizing Antibodies Targeting SARS-CoV-2

Christopher Cowan, Regeneron Pharmaceuticals, United States

10:20 - 10:45 Meeting the challenges of COVID-19 from a CDMO perspective

James Miskin, Oxford Biomedica, United Kingdom

10:45 - 11:15 Morning Break | Garden Lobby (-1)

Oral Session 3: Purification of Biologics with Chemical Synthesis Steps | Salone dei Cavalieri (-1)

Session Chairs: Michaela Wendeler, AstraZeneca, United States

Thanmaya Peram, Genentech, United States

11:15 - 11:20 Introduction by Session Chairs

11:20 - 23:45 Assessment of Impurity & Product Variant Removal Methods for ADCs Conjugated with Novel Payloads

Xin Xin Lin, Genentech, United States

11:45 - 12:10 Oligonucleotide purification strategies and application of process modeling to define control strategy

Pranay Ghosh, Roche, Switzerland, Michelle Butler, Roche, Switzerland

12:10 - 12:35 mRNA-based therapeutics and vaccines - COVID-19 and beyond

Andreas Kuhn, BioNTech SE, Germany

12:35 - 13:30 Lunch (Boxed) | Garden Lobby (-1)

13:30 - 18:30 Afternoon Networking Activities (Optional) | Meeting Point: Congress Foyer (-1)

18:45 - 19:15 Cocktail Reception | Tiepolo Terrace (0)

19:15 - 20:30 Dinner I Tiepolo Terrace (0)

Poster Snapshot Session & Poster Session | Salone dei Cavalieri (-1)

Session Chairs: Ana Azevedo, Instituto Superior Tecnico (IST), Portugal

Glen Bolton, Amgen, United States

Marco Rito-Palomares, Tecnologico de Monterrey, Mexico

20:30 - 21:00 Poster Snapshot Session 1

#2. General approaches and considerations for purification of hydrodynamically large Fab conjugates

Eileen Duenas, Genentech, United States

#7. Machine learning and advanced data analytics to better exploit process analytical technology for chromatography operation Stephen Goldrick, University College London (UCL), United Kingdom

#9. Implementation of novel affinity ligand for Lentiviral vector purification

Ana Sofia Moreira, Instituto de Biologia Experimental e Tecnológica (iBET), Portugal

#12. Production of complex recombinant proteins in plant-based systems – From case studies in process development to regulatory approval

Johannes Buyel, Fraunhofer IME/RWTH Aachen University, Germany

#21. Downstream Bioprocess Challenges of a Novel Class of Nanobodies; Understanding Protein A Capture Step Aggregation Removal, Aggregation Formation and Formulation Utilizing Biophysical Analysis and Computational Modeling Sandra Rios, Merck and Co., Inc., United States

#27. Evaluation of Ecofriendly Alternatives for a Virus Inactivation Detergent used in Biologics Manufacturing Process Dong Yang, Bristol Myers Squibb, United States

21:00 - 23:00 Poster Session 1 with Desserts and Drinks

Tuesday 12 July 2022

07:00 - 09:00 Breakfast | Le Bella Arti (-1)

Oral Session 4: Separation Sciences in Advancing Novel Gene and Cell Therapies | Salone dei Cavalieri (-1)

Session Chairs: Nooshafarin (Nooshie) Sanaie, Poseida Therapeutics, United States

Andrew Ramelmeier, Sangamo Therapeutics, United States

09:00 - 09:05 Introduction by Session Chairs

09:05 - 09:30 From blood to drug product, the isolation and purification of Treg cells

Pierre Heimendinger, Sangamo Therapeutics, France

09:30 - 09:55 Towards continuous processes for advanced therapy medicinal products

Manuel Carrondo, iBET, Portugal

09:55 - 10:20 Implications of AAV affinity column reuse and processing conditions on product quality attributes

Harshal Soni, Rensselaer Polytechnic Institute, United States

10:20 - 10:45 Removal of Empty AAV Capsids to Undetectable Levels Using Orthogonal Purification Steps – Product Quality and Process Robustness

onsiderations

Rahul Sheth, BioMarin Pharmaceutical Inc., United States

10:45 - 11:15 Morning Break | Garden Lobby (-1)

Oral Session 5: Modeling Next Generation Supply Chains & Facilities: Envisaging the Challenges - Engineering the Solutions | Salone dei Cavalieri (-1)

Session Chairs: Jan Griesbach, Roche, Germany

Nigel Titchener-Hooker, University College London (UCL), United Kingdom

11:15 - 11:20 Introduction by Session Chairs

11:20 - 11:45 Next Generation Bioprocessing – Manufacturing and Facility Concepts

Rob OKeeffe, Eli Lilly / University College Dublin, Ireland

11:45 - 12:10 What do all CGT supply chains have in common? Designing for platform capabilities that bring down CoG and increase the chance of

successful commercialization

Sebastian Schneider, Roche, Switzerland

12:10 - 12:35 Decisional tools for successful commercialisation of cell and gene therapies: industrial case studies

Christos Stamatis, University College London (UCL), United Kingdom

12:35 - 13:45 Lunch Buffet | Le Bella Arti (-1) & Garden Lobby (-1)

<u>Keynote | Salone dei Cavalieri (-1)</u>

Host Arne Staby, Novo Nordisk A/S, Denmark

13:45 - 14:30 Precision Medicine for Cancer Treatment Leveraging Industrialized, Robust and Simple Bispecific Antibody Platform: Learnings from a

10-year Journey

Hanne Bak, Regeneron Pharmaceuticals, United States

14:30 - 14:45 Stretch Break

Oral Session 6: All Roads Lead to Rome - But Which Roads Lead to Accelerated Bioprocess Development? | Salone dei Cavalieri (-1)

Sophie Karkov, Novo Nordisk, Denmark
Giorgio Carta, University of Virginia, United States

14:45 - 14:50	Introduction by Session Chairs
14:50 - 15:15	Scaling Down in HTPD Marcel Ottens, Delft University of Technology, Netherlands
15:15 - 15:40	Predictive Models for Process Development and Multidimensional Real Time Monitoring in Downstream Processing Astrid Duerauer, BOKU & Austrian Centre of Industrial Biotechnology, Austria
15:40 - 16:05	Evolving trends in monoclonal antibody production processes: From 'platforms' to 'pandemic pace' development Sanchayita Ghose, Bristol Myers Squibb, United States
16:05 - 16:30	Rapid downstream process development for a SARS-CoV-2 vaccine candidate through High Throughput Process Development Spyridon Konstantinidis, Merck and Co., Inc., United States
17:00 - 20:00	Vatican Tour Meeting Point: Congress Foyer (-1)
20:00 - 23:00	Dinner (Offsite)

Wednesday 13 July 2022

07:00 - 09:00	Breakfast Le Bella Arti (-1)
08:30 - 13:30	Morning Networking Activities (Optional) Meeting Point: Congress Foyer (-1)
13:00 - 14:00	Lunch (Boxed) & Refresh Garden Lobby (-1)

Keynote | Salone dei Cavalieri (-1)

Host Arne Staby, Novo Nordisk A/S, Denmark

14:00 - 14:45 A Look Back in Order to Look Forward; Analysis of Historical Recovery Progress to Guide Future Innovations in the Biopharmaceutical

Industry

Jill Myers, TG Therapeutics, United States

Oral Session 7: Manufacturability Assessment for Complex Biologics & Gene Therapies | Salone dei Cavalieri (-1)

Session Chairs: Hong Li, Merck and Co., Inc., United States

Juergen Hubbuch, Karlsruhe Institute of Technology, Germany

14:45 - 14:50 Introduction by Session Chairs

14:50 - 15:15 Harnessing AAV Technology and Manufacturing Capabilities to Meet the Needs of the Gene Therapy Market

John Pieracci, Biogen, United States

15:15 - 15:40 Challenges During Recovery and Purification of AAV Gene Therapy

Michael Winkler, Regenxbio, United States

15:40 - 16:05 Predicting antibody developability

Peter Tessier, University of Michigan, United States

16:05 - 16:35 Afternoon Break | Garden Lobby (-1)

Oral Session 8: Big Data Analytics and Modeling in Biomanufacturing | Salone dei Cavalieri (-1)

Session Chairs: Steven Cramer, Rensselaer Polytechnic Institute , United States

Joey Studts, Boehringer Ingelheim, Germany

16:35 - 16:40 Introduction by Session Chairs

16:40 - 17:05 Digital twins for MCSGP: accelerated model development and systematic design

Lisa Vetter-Joss, Novo Nordisk, Denmark

17:05 - 17:30 Smart platform for fast development of small-scale integrated continuous downstream processes

Bernt Nilsson, Lund University, Sweden

17:30 - 17:55 Integrated mechanistic modeling to predict a commercial downstream process

Federico Rischawy, Boehringer Ingelheim / Karlsruhe Institute of Technology (KIT), Germany

17:55 - 18:20 Big Data Analytics for Control of Continuous Processes

Anurag Rathore, Indian Institute of Technology Delhi, India

18:45 - 19:15 Cocktail Reception | Tiepolo Terrace (0)

19:15 - 20:30 Dinner | Michelangelo (0)

Poster Snapshot Session & Poster Session | Salone dei Cavalieri (-1)

Session Chairs: Ana Azevedo, Instituto Superior Tecnico (IST), Portugal

Glen Bolton, Amgen, United States

Marco Rito-Palomares, Tecnologico de Monterrey, Mexico

20:30 - 21:00 Poster Snapshot Session 2

#51. Continuous and integrated processing of viral capsomeres and virus-like particle purification using new generation multi-modal chromatography strategies

Lukas Gerstweiler, University of Adelaide, Australia

#64. To explore novel approaches to remove host cell proteins (HCPs) for antibodies and other Fc fusion proteins' production Tingting Cui, AstraZeneca, United Kingdom

#65. Evolution of a clarification platform strategy using a novel chromatographic clarification technology

Agathe Drapé, Sanofi, France

#66. Designing high density isopore membranes with "à la carte" surface chemistries for downstream mAb purification and applications in cell and gene therapies & diagnostics

Daniele Gerion, Terapore Technologies, United States

#70. 3D printed stationary phases for bioseparations: control of morphology across scales, from mm to μm to nm

Simone Dimartino, University of Edinburgh, United Kingdom

#74. Using real-time data to enable smart decision making on the manufacturing floor

Christine O'Sullivan, Amgen, Ireland

21:00 - 23:00 Poster Session 2 with Desserts & Drinks

Thursday 14 July 2022

07:00 - 09:00 Breakfast | Le Bella Arti (-1)

Oral Session 9: New and Transformative Purification Technologies | Salone dei Cavalieri (-1)

Session Chairs: Raquel Orozco, Bayer, United States

Abraham Lenhoff, University of Delaware, United States

09:00 - 09:05 Introduction by Session Chairs

09:05 - 09:30 Novel Ligands and Modalities for the Purification of Gene Editing Products: CRISPR-Cas and Viral Vectors

Stefano Menegatti, NC State University, United States

09:30 - 09:55 Challenging the Paradigm: An Innovative and Scalable Purification Platform for AAV and Other Biologics

Kelli Luginbuhl, Isolere Bio, United States

09:55 - 10:20 Novel DNA Removal Technology for Exosomes

Aaron Noyes, Codiak BioSciences, United States

10:20 - 10:45 Enabling a design cycle for bioseparation materials with X-ray imaging and 3D printing

Thomas Johnson, University College London (UCL), United Kingdom

10:45 - 11:15 Morning Break | Garden Lobby (-1)

11:15 - 12:45 Roundtables: Yield! | Michelangelo 1/2/3/San Pietro (0)

1. Assessing Protein Manufacturability (Chairs: M Butler (Roche), R Willson (U. Houston))

2. Continuous Processing: Opportunities and Challenges (Chairs: K Brower (Sanofi), A Jungbauer (BOKU))

3. Overcoming Constraints in Gene Therapy Manufacture (Chairs: S D'Costa (Alcyone), A Tustian (Regeneron), J Pieracci (Biogen))

4. Manufacturability for Pandemic Preparedness (Chairs: A Rayat (UCL), G Ferreira (AstraZeneca), B Kelley (Vir))

12:45 - 14:15 Lunch Buffet | Le Bella Arti (-1) & Garden Lobby (-1)

Oral Session 10: Impact of Diverse Expression Systems | Salone dei Cavalieri (-1)

Session Chairs: Jean Bender, Visterra, Inc., United States

Ranga Godavarti, Pfizer, United States

14:15 - 14:20 Introduction by Session Chairs

14:20 - 14:45 The development and manufacture of products from a cell-free expression system

Judy Hsii, Sutro Biopharma, United States

14:45 - 15:10 Insulin Purification – Innovation Continuum via Synthesis of Fundamentals, Technology and Modeling

 $\label{eq:conditional} \textbf{David Roush, Merck and Co., Inc., United States}$

15:10 - 15:35 Why Downstream Teams Should Root for Alternative Expression Hosts

J. Christopher Love, MIT, United States

15:35 - 16:05 Afternoon Break | Garden Lobby (-1)

Oral Session 11: Future Facility Design Concepts | Salone dei Cavalieri (-1)

Session Chairs: Lisa Connell-Crowley, Just - Evotec Biologics, United States

Victor Goetz, Eli Lilly and Company, United States

16:05 - 16:10 Introduction by Session Chairs

16:10 - 16:35 Biopharmaceutical Manufacturing Facilities of the Future: Rigidity, Risk, Resilience, and Veritas' Mirror Jeffrey Baker, NIIMBL, United States
 16:35 - 17:00 Advancing Manufacturing Technology Through a Flexible J.POD® Facility
Robert Casey, Just - Evotec Biologics, Inc., United States
 17:00 - 17:25 A truly continuous counter-current downstream

Keynote | Salone dei Cavalieri (-1)

Host Nihal Tugcu, Sanofi, United States

 $17:25-18:10 \qquad \hbox{ New the rapeutic modalities and Moore's Law in biomanufacturing}$

Jon Coffman, AstraZeneca, United States

Hari Pujar, Tessera Therapeutics and Flagship Pioneering, United States

19:00 - 00:00 Closing Banquet & Awards (Offsite) | Meeting Point: Hotel Lobby (0)

Friday 15 July 2022

07:00 - 10:00	Breakfast & Departures Le Bella Arti (-1)
10:00	RXIX Conference Close